[{"data":1,"prerenderedAt":11},["ShallowReactive",2],{"article-148caf5069fc16dd014a467435be8d25":3},{"_id":4,"slug":4,"title":5,"cover":6,"summary":7,"category":8,"publish_at":7,"read_count":9,"content":10,"blocks_json":7},"148caf5069fc16dd014a467435be8d25","30项获批！博鳌乐城又一细胞应用技术获批收费，治疗项目汇总（含收费价格、落地医院）","https://6875-huali-cell-8geyb3yje6a285d1-1419749029.tcb.qcloud.la/assets/cover/1778128902298-ScreenShot_2026-05-07_124119_232.png","","细胞文献",84,"\u003Ch2>近日，乐城医疗药品监管局正式批复，同意\u003Cspan class=\"\" link-id=\"link-1778128405322-0.16586910395950394\">博鳌国际医院\u003C/span>开展应用无支架球型软骨组织颗粒（CartiLife）修复膝关节软骨缺损的自体软骨细胞应用技术临床应用，这意味着又一项前沿细胞应用技术正式进入可收费临床转化阶段。\u003C/h2>\n\u003Cp>\u003Csection data-mpa-md-key=\"heading-1\" style=\"margin-bottom: 16px;margin-top: 16px;font-family: Optima-Regular, PingFangTC-light;\">\u003Csection style=\"width: 100%;display: flex;justify-content: center;align-items: center;\">\u003Csection style=\"display: flex;justify-content: flex-start;align-items: center;flex-direction: column;\" data-mid=\"\">\u003Csection mpa-none-content=\"t\" style=\"text-align: center;\" data-mid=\"\">\u003Cp style=\"font-weight: bold;font-size: 17px;color: #6BA0FF;line-height: 24px;\" data-mid=\"\" data-mpa-md-heading-idx=\"01\" mpa-none-content=\"t\">\u003Cspan leaf=\"\">PART 01\u003C/span>\u003C/p>\u003C/section>\u003Csection style=\"display: flex;justify-content: flex-start;align-items: center;flex-direction: column;\" data-mid=\"\">\u003Csection mpa-none-content=\"t\" style=\"width: 50px;height: 10px;align-self: flex-start;margin-left: -12px;margin-bottom: -8px;background: linear-gradient(270deg, rgba(147, 184, 251, 0) 0%, #93B8FB 100%);\" data-mid=\"\">\u003Cspan leaf=\"\">\u003Cbr>\u003C/span>\u003C/section>\u003Csection style=\"text-align: center;z-index: 1;\" data-mid=\"\">\u003Csection data-mpa-md-content=\"t\" style=\"font-weight: bold; font-size: 18px; color: rgb(49, 49, 49); letter-spacing: 1px;\" data-mid=\"\" data-mpa-md-action-id=\"$id\">\u003Cspan leaf=\"\">技术核心：自体软骨细胞修复，精准针对中重度软骨缺损\u003C/span>\u003C/section>\u003C/section>\u003Csection mpa-none-content=\"t\" style=\"width: 50px;height: 10px;margin-right: -12px;margin-top: -10px;align-self: flex-end;background: linear-gradient(-270deg, rgba(147, 184, 251, 0) 0%, #93B8FB 100%);\" data-mid=\"\">\u003Cspan leaf=\"\">\u003Cbr>\u003C/span>\u003C/section>\u003C/section>\u003C/section>\u003C/section>\u003C/section>\u003Csection data-mpa-md-key=\"common\" style=\"margin-bottom: 16px; margin-top: 16px; font-family: Optima-Regular, PingFangTC-light; color: rgb(51, 51, 51);\">\u003Cspan leaf=\"\">\u003Cbr>\u003C/span>\u003C/section>\u003Csection data-mpa-md-key=\"text\" style=\"margin-bottom: 16px; color: rgb(51, 51, 51); margin-top: 16px; letter-spacing: 1px; font-family: Optima-Regular, PingFangTC-light;\" data-mpa-md-action-id=\"$id\">\u003Cspan leaf=\"\">本次获批技术以自体软骨细胞应用为核心，主要面向膝关节软骨缺损中重度患者，精准匹配国际软骨修复学会（ICRS）分级Ⅲ 级、Ⅳ 级，且缺损面积在2–10 平方厘米的人群，为长期受关节疼痛、活动受限困扰的患者带来全新治疗选择。\u003C/span>\u003C/section>\u003Csection data-mpa-md-key=\"common\" style=\"margin-bottom: 16px; margin-top: 16px; font-family: Optima-Regular, PingFangTC-light; color: rgb(51, 51, 51);\">\u003Cspan leaf=\"\">\u003Cbr>\u003C/span>\u003C/section>\u003Csection data-mpa-md-key=\"heading-1\" style=\"margin-bottom: 16px;margin-top: 16px;font-family: Optima-Regular, PingFangTC-light;\">\u003Csection style=\"width: 100%;display: flex;justify-content: center;align-items: center;\">\u003Csection style=\"display: flex;justify-content: flex-start;align-items: center;flex-direction: column;\" data-mid=\"\">\u003Csection mpa-none-content=\"t\" style=\"text-align: center;\" data-mid=\"\">\u003Cp style=\"font-weight: bold;font-size: 17px;color: #6BA0FF;line-height: 24px;\" data-mid=\"\" data-mpa-md-heading-idx=\"01\" mpa-none-content=\"t\">\u003Cspan leaf=\"\">PART 02\u003C/span>\u003C/p>\u003C/section>\u003Csection style=\"display: flex;justify-content: flex-start;align-items: center;flex-direction: column;\" data-mid=\"\">\u003Csection mpa-none-content=\"t\" style=\"width: 50px;height: 10px;align-self: flex-start;margin-left: -12px;margin-bottom: -8px;background: linear-gradient(270deg, rgba(147, 184, 251, 0) 0%, #93B8FB 100%);\" data-mid=\"\">\u003Cspan leaf=\"\">\u003Cbr>\u003C/span>\u003C/section>\u003Csection style=\"text-align: center;z-index: 1;\" data-mid=\"\">\u003Csection data-mpa-md-content=\"t\" style=\"font-weight: bold; font-size: 18px; color: rgb(49, 49, 49); letter-spacing: 1px;\" data-mid=\"\" data-mpa-md-action-id=\"$id\">\u003Cspan leaf=\"\">技术背景：国际前沿技术，多国权威认证\u003C/span>\u003C/section>\u003C/section>\u003Csection mpa-none-content=\"t\" style=\"width: 50px;height: 10px;margin-right: -12px;margin-top: -10px;align-self: flex-end;background: linear-gradient(-270deg, rgba(147, 184, 251, 0) 0%, #93B8FB 100%);\" data-mid=\"\">\u003Cspan leaf=\"\">\u003Cbr>\u003C/span>\u003C/section>\u003C/section>\u003C/section>\u003C/section>\u003C/section>\u003Csection data-mpa-md-key=\"common\" style=\"margin-bottom: 16px; margin-top: 16px; font-family: Optima-Regular, PingFangTC-light; color: rgb(51, 51, 51);\">\u003Cspan leaf=\"\">\u003Cbr>\u003C/span>\u003C/section>\u003Csection data-mpa-md-key=\"text\" style=\"margin-bottom: 16px; color: rgb(51, 51, 51); margin-top: 16px; letter-spacing: 1px; font-family: Optima-Regular, PingFangTC-light;\" data-mpa-md-action-id=\"$id\">\u003Cspan leaf=\"\">\u003Cspan class=\"\" link-id=\"link-1778128405325-0.8478538212551936\">CartiLife\u003C/span> 无支架球型软骨组织颗粒由韩国 Biosolution 公司研发，技术成熟度与安全性经过多重验证：\u003C/span>\u003C/section>\u003Col style=\"padding-left: 1.2em; color: rgb(37, 37, 37); font-family: Optima-Regular, PingFangTC-light; width: fit-content;\" class=\"list-paddingleft-1\">\u003Cli>\u003Csection style=\"margin-bottom: 8px; color: rgb(51, 51, 51); letter-spacing: 1px;\" data-mpa-md-content=\"t\" data-mpa-md-key=\"ordered-list\" data-mpa-md-action-id=\"$id\">\u003Cspan leaf=\"\">2019 年：获韩国附条件上市许可\u003C/span>\u003C/section>\u003C/li>\u003Cli>\u003Csection data-mpa-md-content=\"t\" data-mpa-md-action-id=\"$id\" style=\"margin-bottom: 8px; color: rgb(51, 51, 51); letter-spacing: 1px;\">\u003Cspan leaf=\"\">2023 年：获美国 FDA再生医学先进疗法（RMAT）认定\u003C/span>\u003C/section>\u003C/li>\u003Cli>\u003Csection data-mpa-md-content=\"t\" data-mpa-md-action-id=\"$id\" style=\"margin-bottom: 8px; color: rgb(51, 51, 51); letter-spacing: 1px;\">\u003Cspan leaf=\"\">2025 年 3 月：获美国 FDA正式上市许可\u003C/span>\u003C/section>\u003C/li>\u003C/ol>\u003Csection data-mpa-md-key=\"text\" style=\"margin-bottom: 16px; color: rgb(51, 51, 51); margin-top: 16px; letter-spacing: 1px; font-family: Optima-Regular, PingFangTC-light;\" data-mpa-md-action-id=\"$id\">\u003Cspan leaf=\"\">2026 年，该技术作为生物医学新技术引入\u003Cspan class=\"\" link-id=\"link-1778128405326-0.7466448901085443\">博鳌乐城先行区\u003C/span>，由博鳌国际医院在符合 GMP 标准的生物制剂车间完成生产，在骨科科室实现规范临床应用。\u003C/span>\u003C/section>\u003Csection data-mpa-md-key=\"common\" style=\"margin-bottom: 16px; margin-top: 16px; font-family: Optima-Regular, PingFangTC-light; color: rgb(51, 51, 51);\">\u003Cspan leaf=\"\">\u003Cbr>\u003C/span>\u003C/section>\u003Csection data-mpa-md-key=\"heading-1\" style=\"margin-bottom: 16px;margin-top: 16px;font-family: Optima-Regular, PingFangTC-light;\">\u003Csection style=\"width: 100%;display: flex;justify-content: center;align-items: center;\">\u003Csection style=\"display: flex;justify-content: flex-start;align-items: center;flex-direction: column;\" data-mid=\"\">\u003Csection mpa-none-content=\"t\" style=\"text-align: center;\" data-mid=\"\">\u003Cp style=\"font-weight: bold;font-size: 17px;color: #6BA0FF;line-height: 24px;\" data-mid=\"\" data-mpa-md-heading-idx=\"01\" mpa-none-content=\"t\">\u003Cspan leaf=\"\">PART 03\u003C/span>\u003C/p>\u003C/section>\u003Csection style=\"display: flex;justify-content: flex-start;align-items: center;flex-direction: column;\" data-mid=\"\">\u003Csection mpa-none-content=\"t\" style=\"width: 50px;height: 10px;align-self: flex-start;margin-left: -12px;margin-bottom: -8px;background: linear-gradient(270deg, rgba(147, 184, 251, 0) 0%, #93B8FB 100%);\" data-mid=\"\">\u003Cspan leaf=\"\">\u003Cbr>\u003C/span>\u003C/section>\u003Csection style=\"text-align: center;z-index: 1;\" data-mid=\"\">\u003Csection data-mpa-md-content=\"t\" style=\"font-weight: bold; font-size: 18px; color: rgb(49, 49, 49); letter-spacing: 1px;\" data-mid=\"\" data-mpa-md-action-id=\"$id\">\u003Cspan leaf=\"\">乐城先行区累计获批：30 项前沿生物医学技术落地\u003C/span>\u003C/section>\u003C/section>\u003Csection mpa-none-content=\"t\" style=\"width: 50px;height: 10px;margin-right: -12px;margin-top: -10px;align-self: flex-end;background: linear-gradient(-270deg, rgba(147, 184, 251, 0) 0%, #93B8FB 100%);\" data-mid=\"\">\u003Cspan leaf=\"\">\u003Cbr>\u003C/span>\u003C/section>\u003C/section>\u003C/section>\u003C/section>\u003C/section>\u003Csection data-mpa-md-key=\"common\" style=\"margin-bottom: 16px; margin-top: 16px; font-family: Optima-Regular, PingFangTC-light; color: rgb(51, 51, 51);\">\u003Cspan leaf=\"\">\u003Cbr>\u003C/span>\u003C/section>\u003Csection data-mpa-md-key=\"text\" style=\"margin-bottom: 16px; color: rgb(51, 51, 51); margin-top: 16px; letter-spacing: 1px; font-family: Optima-Regular, PingFangTC-light;\" data-mpa-md-action-id=\"$id\">\u003Cspan leaf=\"\">截至目前，博鳌乐城国际医疗旅游先行区已累计获批30 项前沿生物医学新技术临床应用资格，覆盖干细胞应用、免疫细胞应用、基因应用三大核心方向，聚焦肿瘤、神经退行性疾病、肺与肝功能损伤、血液病、关节退行性病等重大疾病领域，持续领跑国内细胞应用临床转化。\u003C/span>\u003C/section>\u003Csection data-mpa-md-key=\"common\" style=\"margin-bottom: 16px; margin-top: 16px; font-family: Optima-Regular, PingFangTC-light; color: rgb(51, 51, 51);\">\u003Csection style=\"text-align: center;\" nodeleaf=\"\">\u003Cspan style=\"letter-spacing: 1px;\">从国际获批到国内落地，从技术引进到规范生产，博鳌乐城正加速推动全球前沿细胞应用技术惠及中国患者，为再生医学与精准医疗发展注入强劲动力。\u003C/span>\u003C/section>\u003C/section>\u003C/p>\n\u003Cfigure class=\"img-block\">\u003Cimg src=\"https://6875-huali-cell-8geyb3yje6a285d1-1419749029.tcb.qcloud.la/assets/image/1778129034346-640__1_.jpg\" alt=\"640 (1)\" />\u003Cfigcaption>640 (1)\u003C/figcaption>\u003C/figure>\n\u003Cp>\u003C/p>\n\u003Cp>\u003C/p>",1779368112770]